Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.4.3 was added to the history. Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedAdded a new revision label (v3.4.2) to the record history and removed older notices (v3.4.1 and the funding-status notice). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check40 days agoChange DetectedA government funding lapse notice was added and the record history shows a new Revision: v3.4.1 (replacing v3.4.0); these are administrative updates and do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check47 days agoChange DetectedAdded a glossary toggle and color-coded highlights for added/deleted items. Updated revision notes to v3.4.0 (replacing v3.3.4).SummaryDifference1%

- Check61 days agoChange DetectedRevision history updated to include v3.3.4 and remove v3.3.3 for the study NCT04293276.SummaryDifference0.1%

- Check82 days agoChange DetectedThe page history now shows a new revision (v3.3.3); the HHS Vulnerability Disclosure link and the older revision (v3.3.2) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.